Taiwan · Delayed Price · Currency is TWD DV Biomed Statistics
Total Valuation
DV Biomed has a market cap or net worth of TWD 973.97 million. The enterprise value is 652.06 million.
| Market Cap | 973.97M |
| Enterprise Value | 652.06M |
Important Dates
The next estimated earnings date is Thursday, August 20, 2026.
| Earnings Date | Aug 20, 2026 |
| Ex-Dividend Date | Aug 27, 2026 |
Share Statistics
DV Biomed has 24.35 million shares outstanding. The number of shares has increased by 0.07% in one year.
| Current Share Class | 24.35M |
| Shares Outstanding | 24.35M |
| Shares Change (YoY) | +0.07% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 15.88% |
| Owned by Institutions (%) | n/a |
| Float | 3.58M |
Valuation Ratios
The trailing PE ratio is 12.67.
| PE Ratio | 12.67 |
| Forward PE | n/a |
| PS Ratio | 1.22 |
| PB Ratio | 1.77 |
| P/TBV Ratio | 1.78 |
| P/FCF Ratio | 19.33 |
| P/OCF Ratio | 13.87 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.19, with an EV/FCF ratio of 12.94.
| EV / Earnings | 8.51 |
| EV / Sales | 0.82 |
| EV / EBITDA | 6.19 |
| EV / EBIT | 8.79 |
| EV / FCF | 12.94 |
Financial Position
The company has a current ratio of 3.76, with a Debt / Equity ratio of 0.07.
| Current Ratio | 3.76 |
| Quick Ratio | 2.79 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.35 |
| Debt / FCF | 0.73 |
| Interest Coverage | 67.16 |
Financial Efficiency
Return on equity (ROE) is 14.97% and return on invested capital (ROIC) is 26.78%.
| Return on Equity (ROE) | 14.97% |
| Return on Assets (ROA) | 6.71% |
| Return on Invested Capital (ROIC) | 26.78% |
| Return on Capital Employed (ROCE) | 12.89% |
| Weighted Average Cost of Capital (WACC) | 4.54% |
| Revenue Per Employee | 2.44M |
| Profits Per Employee | 235,018 |
| Employee Count | 326 |
| Asset Turnover | 1.15 |
| Inventory Turnover | 2.05 |
Taxes
In the past 12 months, DV Biomed has paid 16.71 million in taxes.
| Income Tax | 16.71M |
| Effective Tax Rate | 17.84% |
Stock Price Statistics
The stock price has decreased by -19.85% in the last 52 weeks. The beta is 0.07, so DV Biomed's price volatility has been lower than the market average.
| Beta (5Y) | 0.07 |
| 52-Week Price Change | -19.85% |
| 50-Day Moving Average | 41.37 |
| 200-Day Moving Average | 50.91 |
| Relative Strength Index (RSI) | 38.99 |
| Average Volume (20 Days) | 1,840 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DV Biomed had revenue of TWD 795.19 million and earned 76.62 million in profits. Earnings per share was 3.14.
| Revenue | 795.19M |
| Gross Profit | 576.72M |
| Operating Income | 74.21M |
| Pretax Income | 93.69M |
| Net Income | 76.62M |
| EBITDA | 88.34M |
| EBIT | 74.21M |
| Earnings Per Share (EPS) | 3.14 |
Balance Sheet
The company has 358.56 million in cash and 36.65 million in debt, with a net cash position of 321.91 million or 13.22 per share.
| Cash & Cash Equivalents | 358.56M |
| Total Debt | 36.65M |
| Net Cash | 321.91M |
| Net Cash Per Share | 13.22 |
| Equity (Book Value) | 549.61M |
| Book Value Per Share | 22.58 |
| Working Capital | 399.61M |
Cash Flow
In the last 12 months, operating cash flow was 70.24 million and capital expenditures -19.85 million, giving a free cash flow of 50.39 million.
| Operating Cash Flow | 70.24M |
| Capital Expenditures | -19.85M |
| Depreciation & Amortization | 14.12M |
| Net Borrowing | -17.87M |
| Free Cash Flow | 50.39M |
| FCF Per Share | 2.07 |
Margins
Gross margin is 72.53%, with operating and profit margins of 9.33% and 9.63%.
| Gross Margin | 72.53% |
| Operating Margin | 9.33% |
| Pretax Margin | 11.78% |
| Profit Margin | 9.63% |
| EBITDA Margin | 11.11% |
| EBIT Margin | 9.33% |
| FCF Margin | 6.34% |
Dividends & Yields
This stock pays an annual dividend of 0.60, which amounts to a dividend yield of 1.43%.
| Dividend Per Share | 0.60 |
| Dividend Yield | 1.43% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.07% |
| Shareholder Yield | 1.36% |
| Earnings Yield | 7.87% |
| FCF Yield | 5.17% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 28, 2025. It was a forward split with a ratio of 1.18.
| Last Split Date | Aug 28, 2025 |
| Split Type | Forward |
| Split Ratio | 1.18 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |